Investigating the highly specific adsorber in a clinical trial in patients with severe myocardial infarction (STEMI), showed a significant and relevant reduction in scar size as well as improved cardiac performance after CRP reduction. The extracorporeal application of the PentraSorb® CRP is comparable to dialysis and similar procedures are established practices in the outpatient and inpatient sectors.
For apheresis, the blood plasma is first separated and pumped through the PentraSorb® CRP. The CRP-depleted plasma is then returned to the patient. The PentraSorb® CRP can be regenerated so that several cycles of CRP depletion are possible.
To use the PentraSorb® CRP, two devices are required: a primary device for blood-plasma separation and a secondary device to control the apheresis cycles. Currently, there is a programme for CRP apheresis available for the secondary device ADAsorb® (Medicap Clinic). All standard clinical filter devices and centrifuges compatible with the ADAsorb® can be used a the primary device.
PentraSorb® CRP and the corresponding treatment sets can be ordered through us or our distribution partners. Please contact us here.